NZ334941A - Methods for treating infections using proteins which induce an immune response in one animal species but not in another - Google Patents

Methods for treating infections using proteins which induce an immune response in one animal species but not in another

Info

Publication number
NZ334941A
NZ334941A NZ334941A NZ33494197A NZ334941A NZ 334941 A NZ334941 A NZ 334941A NZ 334941 A NZ334941 A NZ 334941A NZ 33494197 A NZ33494197 A NZ 33494197A NZ 334941 A NZ334941 A NZ 334941A
Authority
NZ
New Zealand
Prior art keywords
proteins
antisera
antibodies
hiv
human
Prior art date
Application number
NZ334941A
Other languages
English (en)
Inventor
Frank B Gelder
Original Assignee
Probe Internat
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Probe Internat filed Critical Probe Internat
Priority to NZ507680A priority Critical patent/NZ507680A/xx
Publication of NZ334941A publication Critical patent/NZ334941A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1054—Lentiviridae, e.g. HIV, FIV, SIV gag-pol, e.g. p17, p24
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/5555—Muramyl dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Dermatology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NZ334941A 1996-10-10 1997-10-10 Methods for treating infections using proteins which induce an immune response in one animal species but not in another NZ334941A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ507680A NZ507680A (en) 1996-10-10 1997-10-10 Immunomodulators and carriers for immunogenic peptides comprising multiple repeats of muramyl dipeptide

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2819496P 1996-10-10 1996-10-10
PCT/US1997/018257 WO1998015658A1 (en) 1996-10-10 1997-10-10 Compositions and methods for treating viral infections

Publications (1)

Publication Number Publication Date
NZ334941A true NZ334941A (en) 2000-11-24

Family

ID=21842081

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ334941A NZ334941A (en) 1996-10-10 1997-10-10 Methods for treating infections using proteins which induce an immune response in one animal species but not in another

Country Status (12)

Country Link
US (6) US6043347A (xx)
EP (1) EP0939835A4 (xx)
JP (2) JP2001502315A (xx)
KR (2) KR100667121B1 (xx)
CN (1) CN1327896C (xx)
AU (1) AU732809B2 (xx)
BR (1) BR9712289A (xx)
CA (1) CA2268372C (xx)
HK (1) HK1023371A1 (xx)
MX (1) MXPA02010374A (xx)
NZ (1) NZ334941A (xx)
WO (1) WO1998015658A1 (xx)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100667121B1 (ko) * 1996-10-10 2007-01-12 프로브 인터내쇼날 바이러스 감염증 치료를 위한 조성물 및 방법
US7157091B1 (en) * 1999-06-18 2007-01-02 Ludwig Institute For Cancer Research MAGE-A1 peptides presented by HLA class II molecules
US6599441B1 (en) * 2000-07-18 2003-07-29 Emerald Biostructures, Inc. Crystallization solutions
CN1339319A (zh) * 2000-08-18 2002-03-13 清华大学 一种治疗艾滋病的药物及其制备方法
US6987184B2 (en) * 2001-02-15 2006-01-17 Signal Pharmaceuticals, Llc Isothiazoloanthrones, isoxazoloanthrones, isoindolanthrones and derivatives thereof as JNK inhibitors and compositions and methods related
WO2004091491A2 (en) * 2003-04-10 2004-10-28 Transform Pharmaceuticals, Inc. Profiling conformational variants, antibody compositions and methods of using the same
US7206991B2 (en) * 2003-10-15 2007-04-17 Lsi Logic Corporation Method, apparatus and program for migrating between striped storage and parity striped storage
US7311928B2 (en) * 2003-12-09 2007-12-25 Briant Burke Topical compositions containing tea tree oil for treatment of viral lesions
US7723063B2 (en) * 2004-04-28 2010-05-25 Intrinsic Lifesciences Methods for measuring levels of bioactive human hepcidin
US20060110405A1 (en) * 2004-08-20 2006-05-25 Buckheit Robert W Jr Plasma or serum fraction for treatment and prevention of viral infections and related conditions
US20090130774A1 (en) * 2005-01-13 2009-05-21 David Peretz Elisa assays using prion-specific peptide reagents
EP1855112A1 (en) * 2006-05-10 2007-11-14 Inserm Method for the in vitro screening of compounds inhibiting production of infectious HIV-1 virions
US8200520B2 (en) 2007-10-03 2012-06-12 International Business Machines Corporation Methods, systems, and apparatuses for automated confirmations of meetings
WO2009123480A1 (en) 2008-04-01 2009-10-08 Virionyx Corporation Ltd Anti-infective agents and uses thereof
BRPI0906311A2 (pt) * 2008-04-01 2016-07-05 Innate Therapeutics Ltd "uso de um muramil dipeptídeo reticulado em uma micropartícula e composição farmacêutica dotada de atividade neoplásica"
NZ571665A (en) * 2008-09-30 2011-01-28 Innate Therapeutics Ltd Compositions and methods for treatment of radiation exposure utilising cross-linked muramyl dipeptide microparticles
US9066983B2 (en) 2009-05-18 2015-06-30 National University Corporation Tokyo Medical And Dental University Peptidic antigen that induces antibody recognizing three-dimensional structure of HIV and method for synthesizing same
NZ577731A (en) * 2009-06-16 2010-08-27 Innate Therapeutics Ltd Compositions and methods for treatment of multiple sclerosis
AU2011230619C1 (en) 2010-03-25 2016-06-23 Oregon Health & Science University CMV glycoproteins and recombinant vectors
RU2517084C2 (ru) * 2010-08-06 2014-05-27 Олег Ильич Эпштейн Способ и средство для ингибирования продукции или усиления элиминации белка р24
WO2012137479A1 (ja) 2011-04-04 2012-10-11 国立大学法人東京医科歯科大学 Ｈｉｖ立体構造認識抗体誘導ペプチド
LT2691530T (lt) 2011-06-10 2018-08-10 Oregon Health & Science University Cmv glikoproteinai ir rekombinantiniai vektoriai
US20130189754A1 (en) 2011-09-12 2013-07-25 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
EP2679596B1 (en) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 env glycoprotein variant
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3072901A1 (en) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
CN114605505B (zh) * 2018-08-09 2023-01-31 东莞市朋志生物科技有限公司 用于检测hiv-1的合成肽
AU2022208435A1 (en) 2021-01-18 2023-08-10 Conserv Bioscience Limited Coronavirus immunogenic compositions, methods and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5528933A (en) * 1978-08-21 1980-02-29 Dai Ichi Seiyaku Co Ltd Muramyldipeptide dimer
CA1341423C (en) * 1984-10-31 2003-03-04 Paul A. Luciw Recombinant proteins of viruses associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome
US4946945A (en) * 1987-06-23 1990-08-07 Allergy Immuno Technologies, Inc. Immunotherapy agents for treatment of IgE mediated allergies
US5128319A (en) * 1987-08-28 1992-07-07 Board Of Regents, The University Of Texas System Prophylaxis and therapy of acquired immunodeficiency syndrome
CA2025634A1 (en) * 1989-09-19 1991-03-20 Thomas Fuerst Peptides including ctl epitopes of hiv proteins and use thereof
US6565842B1 (en) 1995-06-07 2003-05-20 American Bioscience, Inc. Crosslinkable polypeptide compositions
KR100667121B1 (ko) * 1996-10-10 2007-01-12 프로브 인터내쇼날 바이러스 감염증 치료를 위한 조성물 및 방법

Also Published As

Publication number Publication date
US6670181B2 (en) 2003-12-30
US6043347A (en) 2000-03-28
HK1023371A1 (en) 2000-09-08
AU732809B2 (en) 2001-05-03
CA2268372A1 (en) 1998-04-16
JP2001502315A (ja) 2001-02-20
US20040141996A1 (en) 2004-07-22
EP0939835A1 (en) 1999-09-08
EP0939835A4 (en) 2004-10-27
CN1234078A (zh) 1999-11-03
BR9712289A (pt) 1999-08-31
US20070154917A1 (en) 2007-07-05
US6258599B1 (en) 2001-07-10
US6335017B1 (en) 2002-01-01
CA2268372C (en) 2012-11-27
US8110203B2 (en) 2012-02-07
KR100667121B1 (ko) 2007-01-12
KR100547049B1 (ko) 2006-02-01
KR20060041157A (ko) 2006-05-11
AU4813197A (en) 1998-05-05
US20020086034A1 (en) 2002-07-04
MXPA02010374A (es) 2003-04-25
WO1998015658A1 (en) 1998-04-16
KR20000048994A (ko) 2000-07-25
JP2009080118A (ja) 2009-04-16
CN1327896C (zh) 2007-07-25

Similar Documents

Publication Publication Date Title
NZ334941A (en) Methods for treating infections using proteins which induce an immune response in one animal species but not in another
Von Reyn et al. Human immunodeficiency virus infection and routine childhood immunisation
Bishop et al. Humoral immunity in experimental syphilis: I. The demonstration of resistance conferred by passive immunization
Zhang et al. Longevity of Sm-p80-specific antibody responses following vaccination with Sm-p80 vaccine in mice and baboons and transplacental transfer of Sm-p80-specific antibodies in a baboon
Hirsch et al. Effects of anti-thymocyte serum on Rauscher virus infection of mice
Ganz et al. Responses of patients with neoplastic diseases to influenza virus vaccine
EP4226938A3 (en) Coronavirus vaccine
Giordanengo et al. Cruzipain induces autoimmune response against skeletal muscle and tissue damage in mice
WO2023147092A3 (en) Coronavirus vaccine
Lang et al. Suppressant effect of human or equine rabies immunoglobulins on the immunogenicity of post-exposure rabies vaccination under the 2-1-1 regimen: a field trial in Indonesia. MAS054 Clinical Investigator Group.
Shelke et al. Equine rabies immunoglobulin: A review
Ohishi et al. Augmentation of Bovine Leukemia Virus (BLV)‐Specific Lymphocyte Proliferation Responses in Ruminants by Inoculation with BLV env‐Recombinant Vaccinia Virus: Their Role in the Suppression of BLV Replication
Bretscher et al. Vaccination against and treatment of tuberculosis, the leishmaniases and AIDS: perspectives from basic immunology and immunity to chronic intracellular infections
Kempe et al. Smallpox immunization in the United States
Gorse et al. Modulation of immunologic responses to HIV-1MN recombinant gp160 vaccine by dose and schedule of administration
Finerty et al. Mucosal immunization with experimental feline immunodeficiency virus (FIV) vaccines induces both antibody and T cell responses but does not protect against rectal FIV challenge
Dezfulian et al. Role of the mammary tumor virus in the immunogenicity of spontaneous mammary carcinomas of BALB/c mice and in the responsiveness of the hosts
Peckinpaugh et al. Mass enteric live adenovirus vaccination during epidemic ARD
Shearer et al. Alloantigen-based AIDS vaccine: revisiting a" rightfully" discarded promising strategy
Hunsmann et al. Active immunization with feline leukemia virus envelope glycoprotein suppresses growth of virus-induced feline sarcoma
NO890565D0 (no) Forhindring og behandling av retroviral sykdom.
Ter‐Grigorov et al. The stimulating effect of complete Freund's adjuvant on tumour induction by polyoma virus in mice and by Rous sarcoma virus in rats
Ijaz et al. Effect of different routes of immunization with bovine rotavirus on lactogenic antibody response in mice
Hall et al. Boosterable IgE antibody response in mice without the use of adjuvant
CHOW Gonadotropins of the swine pituitary III. Immunological specificity of swine metakentrin

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
ASS Change of ownership

Owner name: INNATE IMMUNOTHERAPEUTICS LIMITED, NZ

Effective date: 20150522

EXPY Patent expired